Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review

Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1-2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have g...

Full description

Saved in:
Bibliographic Details
Published in:Neurology international 2022-01, Vol.14 (1), p.99-108
Main Authors: Nepal, Gaurav, Khurana, Mahika, Bucheli, Domenica Herrera, Bhandari, Siddhartha, Joshi, Utsav, Bhagat, Riwaj, Rehrig, Jessica Holly, Pudasainee, Prasun, Shing, Yow Ka, Ortiz, Juan Fernando, Ojha, Rajeev, Gajurel, Bikram Prasad, Quinonez, Jonathan, Ruxmohan, Samir, Albert, Trevine, Licata, Steven, Stien, Joel
Format: Article
Language:English
Subjects:
Boolean
Bruton tyrosine kinase inhibitor
BTK
Chemotherapy
Clinical trials
Disease control
ibrutinib
Kinases
Lymphoma
Medical prognosis
Mutation
Neurotoxicity
Patients
PCNSL
primary central nervous system lymphoma
Proteins
Radiation therapy
Response rates
Systematic Review
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1-2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.
ISSN:2035-8385
2035-8377
2035-8377
DOI:10.3390/neurolint14010009